Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2022

View Archived Issues

BMAL1 disruption has an impact on metabolic and liver disease

Nanoengineered Bifidobacterium bifidum suppresses tumors in vivo

LABP-73 demonstrates efficacy in preclinical models of chronic asthma

METTL3 inhibition with STM-2457 leads to antitumor effects in OSCC

Study finds variants that increase risk of severe COVID-19

Novartis enters license option agreement with Voyager for AAV capsids for gene therapy programs

Kidney organoids as models of tubular injury reveal a key role of HDR genes in kidney repair

SiteOne Therapeutics patents Nav1.7 inhibitors for pain

Bristol Myers Squibb describes FPR2 and FPR1 agonists

CTLs and arachidonic acid from the tumor microenvironment induce tumor ferroptosis mediated by ACSL4

Local hyperthermia therapy activates beige fat through HSF1 and may be helpful against obesity

Akebia Therapeutics reports prolyl 4-hydroxylase inhibitors

Bridge signs option agreement for CellionBioMed's ion channel modulator for IPF

Dana-Farber Cancer Institute patents USP28 inhibitors for cancer

Sunshine Lake Pharma researchers describe JAK inhibitors

Ixaka's CELTIC-19 targeted nanoparticle product granted ATMP classification

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...